717TiP Randomized, open-label, 3-arm phase III study comparing MK-1308A + lenvatinib and pembrolizumab (pembro) + belzutifan + lenvatinib versus pembro + lenvatinib as first-line (1L) treatment for advanced clear cell renal cell carcinoma (ccRCC)
Year: 2021
Type: article
Source: Annals of Oncology
Institutions: Vanderbilt University, Vanderbilt-Ingram Cancer Center, Fox Chase Cancer Center, Queen Mary University of London, Barts Health NHS Trust, The Royal Free Hospital, Barts Cancer Institute, Memorial Sloan Kettering Cancer Center, Westmead Hospital, Macquarie University, Merck & Co., Inc., Rahway, NJ, USA (United States), Dana-Farber Cancer Institute
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Merck Sharp and Dohme, Eisai Incorporated
OpenAlex ID: W3203861576